v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Operating expenses    
Research and development expenses $ 44,711 $ 27,455
Selling, general and administrative expenses 7,892 6,477
Total operating expenses 52,603 33,932
Operating loss (52,603) (33,932)
Gain (loss) from derivative liabilities 3,315 6,341
Financial investment income 3,914 2,337
Related party loan interest income 0 1,222
Interest expense (2,234) (412)
Other (loss) gain, net (1,734) (229)
Loss before income taxes (49,342) (24,673)
Income tax (benefit) expense (558) 623
Net loss $ (48,784) $ (25,296)
Weighted-average number of shares outstanding – basic (in shares) 303,644 276,263
Weighted-average number of shares outstanding – diluted (in shares) 303,644 276,263
Net loss per share basic (in dollars per share) $ (0.16) $ (0.09)
Net loss per share diluted (in dollars per share) $ (0.16) $ (0.09)

Source